Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

High Sheriff of Oxfordshire Imam Monawar Hussain presents the Outstanding Technical Leadership: Therapeutic Innovation award to Adrian Hill

Part of the High Sheriff of Oxfordshire’s Covid Heroes programme, the awards presented the Institute with the Outstanding Technical Leadership: Therapeutic Innovation honour. This was in recognition of its incredible work to develop, pilot, organise clinical trials for, scale-up and roll-out – in partnership with AstraZeneca – the COVID-19 vaccine in such a short space of time, saving millions of lives across the world.

Professor Adrian Hill KBE, Director of the Jenner Institute & Lakshmi Mittal & Family Professor of Vaccinology who received the award on the Institute’s behalf, said: ‘The COVID-19 vaccine response provides an excellent illustration of the strong links between academia and industry in the UK, with a vaccine candidate from the Jenner Institute at Oxford moving rapidly to many UK industrial partners in early 2021 and then onto many more manufacturing sites internationally – providing over 2 billion doses for 180 countries.’

Read the full story on the University of Oxford website

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.